Kuvendjiska cancers- 2019
Sharon A. O’Toole1,2,3 · Cathy Spillane1,3 · Yanmei Huang1,2,3,4 · Marie C. Fitzgerald1,2,3 · Brendan Ffrench1 · Bashir Mohamed1,3 · Mark Ward1,3 · Michael Gallagher1,3 · Tanya Kelly1,3 · Cathal O’Brien5 · Carmel Ruttle1 · Anna Bogdanska2 · Cara Martin1,3 · Dorinda Mullen1,3 · Elizabeth Connolly3,6 · Sarah A. McGarrigle3,6 · John Kennedy3,7 · John J. O’Leary1,3
Received: 24 March 2020 / Accepted: 27 April 2020 / Published online: 6 May 2020 © The Author(s) 2020
Abstract Purpose The association between pathological complete response (pCR) in patients receiving neoadjuvant chemotherapy (NAC) for breast cancer and Circulating Tumour Cells (CTCs) is not clear. The aim of this study was to assess whether CTC enumeration could be used to predict pathological response to NAC in breast cancer as measured by the Miller–Payne grading system. Methods Twenty-six patients were recruited, and blood samples were taken pre- and post-NAC. CTCs were isolated using the ScreenCell device and stained using a modified Giemsa stain. CTCs were enumerated by 2 pathologists and classified as single CTCs, doublets, clusters/microemboli and correlated with the pathological response as measured by the Miller–Payne grading system. χ2 or ANOVA was performed in SPSS 24.0 statistics software for associations. Results 89% of patients had invasive ductal carcinoma (IDC) and 11% invasive lobular carcinoma (ILC). At baseline 85% of patients had CTCs present, median 7 (0–161) CTCs per 3 ml of whole blood. Post-chemotherapy, 58% had an increase in CTCs. This did not correlate with the Miller–Payne grade of response. No significant association was identified between the number of CTCs and clinical characteristics; however, we did observe a correlation between pre-treatment CTC counts and body mass index, p < 0.05. Conclusions Patients with a complete response to NAC still had CTCs present, suggesting enumeration is not sufficient to aid surgery stratification. Additional characterisation and larger studies are needed to further characterise CTCs isolated pre- and post-chemotherapy. Long-term follow-up of these patients will determine the significance of CTCs in NAC breast cancer patients.
Detection of circulating tumor cells in patients with laryngeal cancer using ScreenCell: Comparative pre- and post-operative analysis and association with prognosis MARIA IDA RIZZO1,2, MASSIMO RALLI3, CHIARA NICOLAZZO4, ANGELA GRADILONE4, RAFFAELLA CARLETTI5, CIRA DI GIOIA5, MARCO DE VINCENTIIS6 and ANTONIO GRECO3 1Department of Surgical Science, Sapienza University of Rome, Rome 00186; 2Craniofacial Center, Plastic and Maxillofacial Surgery Unit, Bambino Gesù Children Hospital, Rome 00165; Departments of 3Sense Organs, 4Molecular Medicine-Circulating Tumor Cells Unit, 5Radiological, Oncological and Pathological Sciences and 6Oral and Maxillofacial Sciences, Sapienza University of Rome, Rome 00186, Italy Received August 10, 2019; Accepted February 20, 2020 DOI: 10.3892/ol.2020.11528
The presence of circulating tumor cells (CTCs) in the blood of patients with metastatic breast, colorectal and prostate cancer have been widely investigated; however, few studies have examined CTCs in patients with laryngeal cancer. The present pilot study aimed to detect pre‑ and postoperative CTCs in the blood of patients with laryngeal cancer and evaluate the association with prognosis. Eight patients with laryngeal squamous cell carcinoma (LSCC) at stage III were included in the present study and underwent total or subtotal laryngectomy and radical bilateral neck lymph node dissection. Blood samples were collected from all patients before and after surgery at different time‑points. The following processing steps were followed; preoperative blood sampling, surgery, postoperative blood sampling at 3, 6 and 12 month follow‑ups, and prognostic association analysis. CTCs were retained on ScreenCell filters for cytological characterization. The presence of CTCs was associated with a less favorable prognosis, whereas a decrease of CTCs in the postoperative sampling was observed in patients who exhibited an improved therapeutic response. The results of the present pilot study revealed a possible association between the presence of CTCs and a less favorable prognosis in patients with LSCC; therefore, these preliminary findings may encourage further research into the incorporation of a liquid biopsy in the management of LSCC, as this may help identify patients with occult metastatic disease earlier and in a non‑invasive manner. In addition, this approach may represent novel independent prognostic factor for use in the clinical evaluation of patients with LSCC.